DAWN-303: Testing whether adding a targeted therapy to standard chemotherapy is safe and effective for people with metastatic pancreatic cancer with a KRAS G12D mutation.A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

Trial purpose

Cancer treatment

Tumor type

Upper gastrointestinal tract

Age

18+

Trial acronym

DAWN-303

Summary

TThis study is looking at whether adding a targeted drug called INCB161734 to standard chemotherapy is safe and works better than standard chemotherapy alone for people with metastatic pancreatic cancer that has a KRAS G12D mutation.

Who can take part?
You may be eligible for this study if:

• you have pancreatic ductal adenocarcinoma (PDAC)
• your cancer has spread to other parts of the body (metastatic)
• your cancer has a KRAS G12D mutation
• you have not received drug treatment for your metastatic cancer before.

If you received treatment when your cancer was at an earlier stage, you may still be eligible. Speak with your doctor or the study team to find out.

What does participation involve?
If you join this study, you will be randomly assigned (by chance) to one of two treatment groups:

• INCB161734 plus standard chemotherapy
• Placebo plus standard chemotherapy

Conditions

This trial is treating people with previously untreated, metastatic pancreatic ductal adenocarcinoma